How to Choose GLP-1 Drugs? Semaglutide and Tirzepatide Mechanisms
“Weight-loss injections”, “What is Semaglutide” — the GLP-1 pathway is one of the most important mechanisms in metabolic medicine in recent years. This article covers only mechanisms and differences.
What Is GLP-1?
Section titled “What Is GLP-1?”Glucagon-like peptide-1 (GLP-1) is an incretin secreted by the gut after eating:
- Glucose-dependent stimulation of insulin secretion.
- Suppresses glucagon.
- Delays gastric emptying.
- Acts on the hypothalamus, enhancing satiety and lowering appetite.
Native GLP-1 has a half-life of only a few minutes; it becomes therapeutic only after drug engineering.
Single Target: GLP-1 Receptor Agonists
Section titled “Single Target: GLP-1 Receptor Agonists”Liraglutide
Section titled “Liraglutide”- Daily dosing, short half-life, finely titratable.
- Well studied for weight-loss and glucose-lowering indications.
Semaglutide
Section titled “Semaglutide”- Long-acting (weekly-dosing class), with greater weight-loss magnitude and improved adherence.
- Core experience: smaller appetite, less interest in high-fat/high-sugar foods, slower gastric emptying.
Dual Target: GLP-1 + GIP
Section titled “Dual Target: GLP-1 + GIP”Tirzepatide
Section titled “Tirzepatide”A dual GIP and GLP-1 receptor agonist:
- GIP enhances nutrient-signal-driven insulin secretion and affects adipose tissue.
- Compared with GLP-1 alone, studies show greater weight-loss and glucose-lowering magnitude.
- Improved body composition (fat down, better relative preservation of lean mass) is widely discussed.
Triple Target: GLP-1 + GIP + GCGR
Section titled “Triple Target: GLP-1 + GIP + GCGR”Retatrutide
Section titled “Retatrutide”Adds action on the glucagon receptor (GCGR):
- Glucagon-receptor activation can promote hepatic thermogenesis, increasing energy expenditure and fat oxidation.
- Weight-loss magnitude at the research frontier; fatty-liver improvement data also draw attention.
- Still appears mostly in development/trial-related research.
The Amylin Route
Section titled “The Amylin Route”Cagrilintide
Section titled “Cagrilintide”A long-acting amylin analog:
- Binding amylin receptors can enhance satiety, delay gastric emptying, and suppress inappropriate glucagon secretion.
- Combined with GLP-1 it is a “dual-pathway appetite suppression” (the CagriSema idea).
How It Works in the Body: Comparison Table
Section titled “How It Works in the Body: Comparison Table”| Drug | Target | One-line mechanism | Subjective feel |
|---|---|---|---|
| Liraglutide | GLP-1 | Daily dosing for glucose control and weight loss | Adjustable day to day |
| Semaglutide | GLP-1 | Long-acting appetite suppression | Weekly dosing |
| Tirzepatide | GIP+GLP-1 | Dual incretin | Greater magnitude |
| Retatrutide | +GCGR | Adds thermogenesis and energy expenditure | Research frontier |
| Cagrilintide | Amylin | Satiety + suppresses glucagon | Often combined |
| Mazdutide | GLP-1+GCG | Appetite control + metabolic preservation | Maintenance-of-metabolic-rate discussion |
Why Some People ‘Rebound’
Section titled “Why Some People ‘Rebound’”After stopping, the appetite center often returns to its original set point and food intake rebounds. So: drugs are tools; protein intake, resistance training, and sleep are the foundation. Body composition (muscle mass) determines metabolic assets.
Common Experience-Level Issues
Section titled “Common Experience-Level Issues”- Nausea, constipation, bloating: related to slower gastric emptying; titrate the dose slowly.
- Muscle loss: protein + resistance training are the key protection.
- Reduced blood glucose swings: related to improved insulin sensitivity.
- Quieter “food noise”: the subjective feel of central appetite regulation.
Related Ingredients and Mechanisms
Section titled “Related Ingredients and Mechanisms”For single-agent and blend entries see Semaglutide, Tirzepatide, Retatrutide; for blend comparisons SM5CAG5 and TR30CAG5. For plateau and visceral-fat strategies see Weight-Loss Plateau, Visceral Fat.
Related Reading
Section titled “Related Reading”For formulations and specs see Metabolism and Weight-Loss Peptides; blends can be compared at SM5CAG5 and TR30CAG5.
Key Registration Trials and Withdrawal Studies
Section titled “Key Registration Trials and Withdrawal Studies”| Reference | Type | Takeaway |
|---|---|---|
| STEP 1 Semaglutide 2.4 mg (PMID: 33567185) | Phase III RCT | Nausea and diarrhea most common, mostly transient |
| SURMOUNT Tirzepatide (PMID: 35658024) | Phase III RCT | Efficacy and safety in obesity |
| Semaglutide 2.4 mg in an East Asian population (PMID: 35131037) | RCT | Significant reduction in visceral fat |
| STEP 1 extension (withdrawal) (PMID: 35441470) | Extension | Weight and metabolic markers rebound after withdrawal |
| Continuation vs withdrawal maintenance (PMID: 33755728) | RCT | The importance of maintenance therapy |
| Body composition review (PMID: 41076575) | Review | Changes in fat and lean mass |
Adverse events: gastrointestinal events are most common, mostly appearing during dose titration and easing over time; some weight regain after withdrawal is expected and needs long-term management.
What It Is
Section titled “What It Is”The naming, structure, and source of this entry; INCI and spec codes are in the table.
How It Works in the Body
Section titled “How It Works in the Body”Receptor/pathway and tissue-level mechanisms; compare with related ingredients.
Common Application Scenarios
Section titled “Common Application Scenarios”Common physiological/skin/metabolic scenarios in research or use.
Safety Boundaries and Limitations
Section titled “Safety Boundaries and Limitations”Evidence hierarchy, no replacement for medical care, and quality/individual-variability limits.
Practical workflow and quality control: before using or comparing an ingredient, see reconstitution, storage, COA, and administration routes; operating standards in Peptide Basics.